Compugen to Participate in Stifel 2025 Healthcare Conference

Compugen Ltd. (Nasdaq: CGEN) is set to participate in the upcoming Stifel 2025 Healthcare Conference in New York City, where members of its management team will engage in a fireside chat. Scheduled for November 11, 2025, from 3:20 to 3:50 PM ET, the conversation aims to provide insights into the company's innovative approaches in the field of cancer immunotherapy. A live webcast of the event will be available on Compugen's Investor Relations webpage, along with a replay post-event.

As a clinical-stage company, Compugen specializes in cancer therapeutics, leveraging its advanced AI-driven computational discovery platform, Unigen™, to identify promising drug targets and biological pathways. Among its leading candidates are COM701, an anti-PVRIG antibody currently in Phase 1 trials, and COM902, which targets the TIGIT protein for treating solid tumors. Notably, the company’s technology has also contributed to the development of Rilvegostomig, a bispecific antibody in Phase 3 trials by AstraZeneca, and GS-0321 (previously known as COM503), a unique anti-IL-18 antibody being developed in collaboration with Gilead.

Compugen remains focused on expanding its therapeutic pipeline, which includes various early-stage immuno-oncology programs aimed at fostering new mechanisms for immune system activation against cancers. Headquartered in Israel, with an additional office in San Francisco, Compugen continues to grow its presence in the biotech space, listed on both Nasdaq and the Tel Aviv Stock Exchange under ticker CGEN.

For further information, interested parties can contact Yvonne Naughton, Ph.D., who heads Investor Relations and Corporate Communications at Compugen.

Compugen Ltd. (Nasdaq: CGEN) is strategically positioned in the clinical-stage cancer immunotherapy sector, actively leveraging its AI/ML-powered computational discovery platform, Unigen™, to identify innovative drug targets. With an upcoming participation at the Stifel 2025 Healthcare Conference, the company presents a unique opportunity for investors to understand its trajectory and innovations in immunotherapy.

Compugen's robust pipeline includes two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT in solid tumors. Notably, the transition of COM902 to collaboration with AstraZeneca reflects the increasing validation of Compugen's technology and its potential for generating best-in-class therapies. The firm’s earlier-stage projects, including the highly promising GS-0321 (formerly COM503), target critical pathways in oncology, presenting multiple avenues for growth.

Investors should closely monitor the upcoming fireside chat for insights into the company's strategic direction, upcoming clinical milestones, and potential partnerships. These discussions will provide a clearer picture of the competitive landscape in cancer immunotherapy, helping to gauge whether Compugen can effectively navigate sector challenges.

Given the increasing investment in cancer therapies and the innovative approaches Compugen employs, its shares present an intriguing opportunity for growth-oriented portfolios. However, potential investors should be cautious; while promising, the clinical stage is fraught with uncertainties, and market reactions can be volatile based on trial outcomes and company announcements.

Considering Compugen’s significant milestones ahead, potential investors may find it valuable to assess the outcomes of ongoing trials and collaborations closely. As the healthcare landscape evolves, keeping abreast of Compugen's progress and prepared for any volatility will be key for those looking to engage with CGEN in their investment strategies.